Global Harmonization of Hemoglobin A1c
Measurement of glycohemoglobin (GHb) is widely used in patients with diabetes mellitus as a monitor of longterm glycemic control (1) (2) (3) . In addition, prospective randomized clinical trials, most notably the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), have demonstrated that GHb is a measure of the risk for the development of diabetes complications (4, 5 ) . GHb is therefore an integral component of the management of patients with diabetes.
GHb comprises several different hemoglobin-glucose adducts, including hemoglobin A1a (HbA1a), HbA1b, and HbA1c. More than 30 different methods are commercially available to measure GHb. Together these factors have led to considerable variation in reference intervals and results reported by different laboratories. When the DCCT was published in 1993, the lack of standardization of GHb methods produced very wide variability among methods, with values ranging from 4.0% to 8.1% on the same blood sample (6 ) . In the United States, the NGSP (previously known as the National Glycohemoglobin Standardization Program) has reduced interlaboratory variation (7 ) . Using a standardization process based on the DCCT reference method, the NGSP has promoted a dramatic improvement in comparability of GHb values among laboratories (3 ) . Data from the 2003 GH2 survey from the College of American Pathologists indicated that Ն98% of participating laboratories use NGSP-certified methods and report results as HbA1c or HbA1c equivalents (3 ). Analogous standardization programs in Sweden and Japan (8, 9 ) , established to harmonize GHb results, have also reduced variability among GHb results. More recently, the IFCC Working Group on HbA1c Standardization prepared primary reference materials of pure HbA1c and HbA0 and developed a reference method for HbA1c (10 ) . They defined HbA1c as the stable adduct of glucose to the N-terminal valine of the ␤-chain of hemoglobin. In the reference method, hemoglobin is cleaved by endoproteinase Glu-C. The resulting glycated and nonglycated N-terminal hexapeptides are separated by HPLC, followed by quantification by electrospray ionization mass spectrometry or capillary electrophoresis (10 question is whether to change the numbers. Changing to the more specific IFCC values could potentially create confusion and will require a long education process. Alternatively, the NGSP values, which were used in both the DCCT and UKPDS and are familiar to clinicians and patients, include substances that are not HbA1c. It was noted that the name of the assay, HbA1c or A1c test, is confusing. Many patients believe the name suggests a blood disorder and has no relationship to diabetes. An important consideration is that the low values (the reference interval for NGSP-certified methods is ϳ4 -6%, whereas that for the IFCC method is 2.8 -3.8%) do not convey to patients that a change of 0.5% has a major impact on health. Patients may gain the erroneous impression that they have improved if reference intervals are lowered. This concept is supported by a study of 49 patients, which indicated that metabolic control deteriorated when the HbA1c results were reported on a lower scale (12 ) .
A retrospective examination of seven-point capillary blood glucose profiles obtained during the DCCT identified a linear relationship between HbA1c and mean blood glucose (MBG) (13 ) . Conversion of the HbA1c values from the study by Rohlfing et al. If this relationship can be confirmed in a prospective study, there will be an opportunity to report HbA1c to indicate mean blood glucose. Advantages of this approach include clear revision of the test with a new reference interval that will avoid confusion (although substantial reeducation will be necessary); a simplification of the range, allowing an individual with diabetes to understand his/her own target value (particularly if already using home glucose monitoring); and increased potential for future use as a diagnostic modality. Disadvantages include the possibility that the simple proportionality may not apply to all populations or to extremes of HbA1c, that results will be reported in different units in different countries (mmol/L and mg/dL), and that instruments will report out a value after manipulation by a conversion factor rather than a direct measurement.
Notwithstanding these caveats, the Workgroup decided to proceed with the innovative approach to implement the new standard. A series of steps were recommended ( Table 2) . The first three recommendations should be executed immediately. The IFCC reference method should be adopted as the global standard for calibration of all instruments and methods that measure HbA1c. Manufacturers have been directed that they should not change the values that are reported. Thus, the DCCT/UKPDS numbers, which are the most widely used at present, should continue to be used. Similarly, the current ranges and numbers should continue to be reported in those countries, e.g., Japan and Sweden, that use values different from those of the DCCT/UKPDS. Several initiatives were proposed for the next 6 months to 3 years. In addition to determining whether there are retrospective data that can link HbA1c to MBG, prospective studies are planned. The goal is to ascertain whether the linear relationship between HbA1c and MBG is confirmed by prospective analysis in different populations world-wide. Finally, programs to inform and educate both professionals and the general public about the new reporting system will be planned.
The recommendations have been endorsed by the ADA, EASD, IDF, and NGSP. The CDC is participating and supports the approach of the initiative. A follow-up meeting was held in September 2004 at which several critical questions that need to be answered were identified: Is there a relationship between HbA1c and MBG in type 1 and type 2 diabetes and in all ethnic groups? Is the relationship the same at different MBG concentrations? Do fluctuations in glucose concentrations at the same MBG value alter HbA1c? Is the relationship between HbA1c and MBG stable when MBG is increasing and decreasing? Do medications or pregnancy alter the relationship?
A subcommittee was established to design the core protocol for the prospective analysis. The charge to the subcommittee includes developing the protocol, preparing a document for the Request for Proposals, participating in selecting the successful proposals, and inviting input into the study design from the experts at the centers selected for participation. The main Working Group will review the proposals and make the final selection. The fundamental concept is that HbA1c will be compared with MBG. The latter will be derived from 48-h continuous glucose monitoring, supplemented by measurement of capillary blood glucose at least eight times a day. Concurrent HbA1c measurements will be performed. Patients with type 1 and type 2 diabetes (in stable glycemic control), as well as healthy controls, will be evaluated. A timetable was established to expedite the process. The protocol should be completed and resources obtained by January 2005. Funds have been set aside by the EASD and The results of the planned studies are expected to enhance our understanding of the relationship between HbA1c and MBG. In addition, it is hoped that the findings will lead to an improved method to monitor long-term glycemic control. It is very encouraging that so many major organizations that have an active interest in improvement of the health of individuals with diabetes are working together on this initiative. We eagerly look forward to true global harmonization of HbA1c.
